A Look At Hims & Hers Health (HIMS) Valuation After Q1 Loss And Lower EBITDA Guidance

Simply Wall St.05-17 23:41

Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit. See our latest analysis for Hims & ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636409003?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-05-17 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636409003","market":"hk","top_or_hot":-1,"title":"A Look At Hims & Hers Health (HIMS) Valuation After Q1 Loss And Lower EBITDA Guidance","media":"Simply Wall St.","content":"<div>\n<p>Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit. See our latest analysis for Hims & ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/a-look-at-hims-hers-health-hims-valuation-after-q1-loss-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Hims & Hers Health (HIMS) Valuation After Q1 Loss And Lower EBITDA Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Hims & Hers Health (HIMS) Valuation After Q1 Loss And Lower EBITDA Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 23:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/a-look-at-hims-hers-health-hims-valuation-after-q1-loss-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit. See our latest analysis for Hims & ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/a-look-at-hims-hers-health-hims-valuation-after-q1-loss-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/a-look-at-hims-hers-health-hims-valuation-after-q1-loss-and","article_id":"2636409003","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/a-look-at-hims-hers-health-hims-valuation-after-q1-loss-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636409003","pubTimestamp":1779032463,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit.\nSee our latest analysis for Hims & Hers Health.\nFollowing the Q1 loss and guidance update, the stock has been volatile, with a 1 day share price return of 3.34%, a year to date share price decline of 25.02%, and a 3 year total shareholder return of 156.40% that highlights how sentiment has swung over time.\nIf this kind of sharp...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMS":"Hims & Hers Health Inc.","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF"},"translate_title":"第一季度亏损和EBITDA指引下调后Hims&Hers Health(HIMS)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMY":0.6,"HIMS":1.98,"HMYY":0.6,"HIMZ":0.6,"HIYY":0.6},"content_text":"Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a net loss of US$92.12 million, reversing last year’s profit. See our latest analysis for Hims & Hers Health. Following the Q1 loss and guidance update, the stock has been volatile, with a 1 day share price return of 3.34%, a year to date share price decline of 25.02%, and a 3 year total shareholder return of 156.40% that highlights how sentiment has swung over time. If this kind of sharp move has your attention, it can be worth widening your watchlist to see which other telehealth and medical platforms are gaining traction in AI enabled care, starting with 32 healthcare AI stocks. So with Hims & Hers guiding to higher 2026 sales but accepting weaker margins and a Q1 loss, is the recent share price slide giving you a mispriced growth story, or is the market already factoring in those ambitions? AdvertisementMost Popular Narrative: 70.9% Undervalued Compared with Hims & Hers Health's last close at $25.05, the most followed narrative points to a fair value of $86.09, a wide gap that has investors asking what assumptions sit underneath that view.  Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock. It is quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco: deliver more value per dollar spent, reinvest scale advantages, and aim to win via customer-centric efficiency.  Read the complete narrative. The narrative leans heavily on rapid subscriber gains, rising monetisation per user, and a generous future profit multiple included in that $86.09 fair value. This raises questions about which growth and margin assumptions would need to hold for that valuation to be supported. Result: Fair Value of $86.09 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on regulation and partner relationships. Tighter GLP-1 scrutiny or further fallout, such as the Novo Nordisk cancellation, could quickly challenge that optimistic setup. Find out about the key risks to this Hims & Hers Health narrative. Another Angle On Valuation There is a twist when you look at Hims & Hers using its P/S ratio instead of the narrative fair value. The stock trades on 2.4x sales, which is expensive versus the US Healthcare industry at 1.2x, but below peers at 4.1x and a fair ratio of 4.9x that the market could move toward. That mix of premium and discount raises the question of whether the risk sits more in expectations or in missing a potential rerating. See what the numbers say about this price — find out in our valuation breakdown. NYSE:HIMS P/S Ratio as at May 2026Next Steps With sentiment this divided, it makes sense to look at the full picture yourself and decide quickly where you stand on Hims & Hers. You can start with 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Hims & Hers is already on your radar, now is the moment to broaden your search and line up the next set of watchlist candidates.  Target potential bargains by checking out quality companies trading at attractive valuations with 51 high quality undervalued stocks. Prioritise resilience by scanning for companies that score well on financial strength using the solid balance sheet and fundamentals stocks screener (45 results). Spot early opportunities that others may be overlooking with the screener containing 21 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hims &amp; Hers Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636409003","isCrawlerRequest":true}